--- title: "Xeris Biopharma Holdings (XERS) news: convertible notes" url: "https://aibio.space/companies/xeris-biopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "XERS convertible notes and lawsuit news: Xeris completes note exchange and conversion; no 2028 convertible notes remain. Xeris Biopharma Holdings, Inc." --- XERS Xeris Biopharma Holdings, Inc. NASDAQ · United States # Xeris Biopharma Holdings (XERS) news XERS convertible notes and lawsuit news Legal · 2026-10-14 ## [Xeris sues Torrent, Rising and others in New Jersey over generic Keveyis patent](https://aibio.space/news/xeris-sues-torrent-rising-others-new-jersey-generic-keveyis-patent/) Xeris Biopharma's subsidiary filed two patent infringement suits on October 13 after a new Keveyis patent was granted. The 8-K names seven defendants. ## Latest Xeris Biopharma Holdings news 1. 2026-07-17 Debt Financing [Xeris completes note exchange and conversion; no 2028 convertible notes remain](https://aibio.space/news/xeris-completes-note-exchange-conversion-no-2028-convertible-notes/) Holders swapped about $23 million of 8.00% notes for about 5.0 million shares and about $23 million in cash. A separate holder converted $10.5 million of notes into about 3.6 million shares. 2. 2026-06-11 Debt Financing [Xeris exchanges $23 million of 2028 convertible notes for cash and stock](https://aibio.space/news/xeris-exchanges-23-million-2028-convertible-notes-cash-stock/) Xeris will retire about $23 million of its 8.00% convertible notes due 2028 for about $23 million in cash plus common stock, with Morgan Stanley as placement agent. About $10.5 million of the notes will remain outstanding. ## Xeris Biopharma Holdings at a glance - **Ticker**: XERS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $121.7 million ### Related companies - [Aura Biosciences](https://aibio.space/companies/aura-biosciences/) NASDAQ: AURA - [Cogent Biosciences](https://aibio.space/companies/cogent-biosciences/) NASDAQ: COGT - [Enzolytics](https://aibio.space/companies/enzolytics/) OTC: ENZC - [Halozyme Therapeutics](https://aibio.space/companies/halozyme-therapeutics/) NASDAQ: HALO - [Conexeu Sciences](https://aibio.space/companies/conexeu-sciences/) NASDAQ: CNXU - [BioCryst Pharmaceuticals](https://aibio.space/companies/biocryst-pharmaceuticals/) NASDAQ: BCRX - [Anavex Life Sciences](https://aibio.space/companies/anavex-life-sciences/) NASDAQ: AVXL - [60 Degrees Pharmaceuticals](https://aibio.space/companies/60-degrees-pharmaceuticals/) NASDAQ: SXTP ### Also on NASDAQ - [Nuvectis Pharma](https://aibio.space/companies/nuvectis-pharma/) NVCT - [Cronos Group](https://aibio.space/companies/cronos/) CRON - [Ocular Therapeutix](https://aibio.space/companies/ocular-therapeutix/) OCUL - [LENZ Therapeutics](https://aibio.space/companies/lenz-therapeutics/) LENZ - [Sana Biotechnology](https://aibio.space/companies/sana-biotechnology/) SANA - [Evogene](https://aibio.space/companies/evogene/) EVGN ## What Xeris Biopharma Holdings does Xeris Biopharma develops and commercializes pharmaceutical products that prioritize its commercial capabilities and proprietary formulation technologies. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged two years and above, and it can be administered in two simple steps. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic and related variants of PPP, a rare genetic, neuromuscular disorder. Its lead pipeline program is XP-8121, which the company is developing as the first and only once-weekly, subcutaneous injection of levothyroxine for hypothyroidism. The company plans to initiate a Phase 3 clinical trial of XP-8121 in 2026. The company says it believes XP-8121 represents a significant commercial opportunity in the United States, with the potential to generate approximately $1 billion in annual net revenue at peak penetration. | Product or program | What it is | Stage | |---|---|---| | Gvoke | Ready-to-use liquid glucagon for severe hypoglycemia | Commercial | | Keveyis | Therapy for hyperkalemic, hypokalemic and related variants of PPP | Approved in the US | | XP-8121 | Once-weekly subcutaneous levothyroxine for hypothyroidism | Phase 3 planned in 2026 | Summarised from the company's [10-K filed Mar 2, 2026](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/xers-20251231.htm). ## Xeris Biopharma Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$31.2 million](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/) | [$25.6 million](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/) | | Net income (loss) | [$554,000](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/) | [-$54.8 million](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/) | | Cash from operations | [$28.6 million](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/) | [-$37.0 million](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/) | | Cash and equivalents | [$111.0 million](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000065/) | [$71.6 million](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/) | | Short-term investments | | [$0](https://www.sec.gov/Archives/edgar/data/1867096/000186709625000039/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $121.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Xeris Biopharma Holdings Has Xeris Biopharma Holdings sold convertible notes? Our latest story on this, dated Jul 17, 2026: "Xeris completes note exchange and conversion; no 2028 convertible notes remain". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/xeris-completes-note-exchange-conversion-no-2028-convertible-notes/). Is Xeris Biopharma Holdings involved in a lawsuit? Our latest story on this, dated Oct 14, 2026: "Xeris sues Torrent, Rising and others in New Jersey over generic Keveyis patent". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/xeris-sues-torrent-rising-others-new-jersey-generic-keveyis-patent/). What is the ticker symbol of Xeris Biopharma Holdings? Xeris Biopharma Holdings, Inc. trades under the ticker XERS on NASDAQ. Where is Xeris Biopharma Holdings listed? Xeris Biopharma Holdings, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:2B30; LSE:0A8E. What is the SEC CIK of Xeris Biopharma Holdings? The SEC Central Index Key (CIK) for Xeris Biopharma Holdings, Inc. is 1867096. Its filings are on SEC EDGAR. How many shares does Xeris Biopharma Holdings have outstanding? 182,320,306 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Xeris Biopharma Holdings listed under? Our directory records Xeris Biopharma Holdings, Inc. under United States. What does Xeris Biopharma Holdings do? Our directory classifies Xeris Biopharma Holdings, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Xeris Biopharma Holdings? The ISIN recorded for Xeris Biopharma Holdings, Inc. is US98422E1038. Does aibio.space cover Xeris Biopharma Holdings? aibio.space lists Xeris Biopharma Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What does Xeris Biopharma Holdings develop? Xeris Biopharma develops and commercializes pharmaceutical products that prioritize its commercial capabilities and proprietary formulation technologies. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged two years and above, and it can be administered in two simple steps. What is Gvoke from Xeris Biopharma Holdings? Gvoke: Ready-to-use liquid glucagon for severe hypoglycemia Stage: Commercial. What is Keveyis from Xeris Biopharma Holdings? Keveyis: Therapy for hyperkalemic, hypokalemic and related variants of PPP Stage: Approved in the US. Is Xeris Biopharma Holdings profitable? Xeris Biopharma Holdings, Inc. reported net income of $554,000 for the fiscal year ended Dec 31, 2025, and generated $28.6 million of cash from operations, per its annual report to the SEC. How much does Xeris Biopharma Holdings spend on research and development? $31.2 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Xeris Biopharma Holdings Members talk about Xeris Biopharma Holdings (XERS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Xeris Biopharma Holdings, newest first. Each line links the filing it comes from. 1. 2026-07-17 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000055/xers-20260715.htm) 2. 2026-06-11 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000045/exh991exchangeofconvertibl.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:XERS on TradingView](https://www.tradingview.com/symbols/NASDAQ-XERS/). ## SEC filings and registration - **SEC name**: Xeris Biopharma Holdings, Inc. - **CIK**: 1867096 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: XERS (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607 - **Phone**: 844-445-5704 - **Shares outstanding**: 182,320,306 as of 2026-07-31 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000091/xers-20261013.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/xers-20260909.htm) filed 2026-09-09 - [10-Q](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000065/xers-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000063/xers-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000055/xers-20260715.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000048/xers-20260629.htm) filed 2026-06-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000045/xers-20260610.htm) filed 2026-06-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000034/xers-20260604.htm) filed 2026-06-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001867096), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Xeris Biopharma Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker XERS, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Xeris Biopharma Holdings, Inc. - **Ticker**: XERS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US98422E1038 - **Other listed symbols**: GETTEX:2B30; LSE:0A8E - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-XERS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/xeris-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Xeris Biopharma Holdings (XERS) news: convertible notes", 2026-10-31, https://aibio.space/companies/xeris-biopharma/